Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

KB2115 (eprotirome) can safely extend the hair growth phase without damaging cells or changing hair color.

Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.

Blocking YAP/TAZ could be a new way to treat skin cancer.

Ruxolitinib treatment may cause eyelash growth.

The treatment was ineffective in humans.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.

Targeting lipid metabolism can help treat advanced, resistant cancers.

A 60-year-old man with Cronkhite-Canada syndrome improved with treatment, but the condition has a high mortality rate and a risk of colorectal cancer.

Some cancer treatments can cause abnormal fine hair growth.

Estrogen and MLL enzymes work together to regulate genes important for hair growth and leukemia.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

Vitamin E in the diet might help protect against hair loss caused by the chemotherapy drug doxorubicin in rabbits.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Chemotherapy for leukemia led to full hair regrowth in a child with alopecia totalis.

Kang'ai injection with FLO chemotherapy improves effectiveness and quality of life in advanced gastric cancer patients.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

Chemotherapy affects blood vessels in hair follicles, not stem cells, allowing hair regrowth.

TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.

YH0618 helps reduce chemotherapy-induced hair loss by targeting specific proteins and pathways.

Removing lymph nodes does not improve survival for advanced ovarian cancer and may cause more complications.

Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.

Patients prioritize quality of life, overall survival, and progression-free survival in treatment decisions for advanced breast cancer.